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CHAPTER TWENTY -TWO

Division of Clinical
Pharmacology
WILLIAM

B.

ABRAMS,

M.D.

AND PETER

H.

VLASSES, PHARM.

D.

"The Lord hath created medicines out of
the earth; and he that is wise will not
abhor them.J)
-ECCLESIASTICUS 38:4

LINICAL pharmacology is the study of
drugs in man. Its two principal
components are drug disposition (the effect
of the body on the drug) and pharmacodynamics
(the eHect of tile drug on the body). These broad
categories have been expanded and combined over
the years so that investigations reported under this
label have ranged from receptor studies to
controlled clinical trials.
The discipline of clinical pharmacology emerged
in tilis country in the 19505, led by studies of
cardiovascular drugs by Harry Gold at Cornell and
of human drug metabolism at the Goldwater
Memorial Hospital in New York City, and by
cardiovascular pharmacology progran1s at the
National Institutes of Health. Academic clinical
pharmacology units appeared at Johns Hopkins,
Emory, Kansas, Yale, Vanderbilt, and many other
wliversities. The study of drugs in man is, of

C

course, of prime interest to the pharmaceutical
industry. Industry-sponsored clinical pharmacology
programs thus came on the scene at the same
time, modeled after the Lilly unit in Indianapolis,
which had been in operation since 1927. Other
successful early units were sponsored by HoffmannLa Roche, Upjohn, and Parke-Davis.

Clinical Pharmacology at
Jefferson
Clinical pharmacology, as a special field, was
introduced to Jefferson in 1966. In that year, the
Smith, Kline & French Foundation provided
fWlds to develop a joint Division of Clinical
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Pharmacology in the Departments of Medicine
and Pharmacology. Dr. John Capelli (Jefferson,
1962) was appointed Director in 1968.
Dr. Capelli pursued his fellowship training at
the Michael Reese Hospital and Jefferson.
Following his year as Chief Medical Resident, he
was appointed Director of the Division of Clinical
Pharmacology and a member of the Division of
Nephrology. Dr. Lawrence Wesson was made a
member of the Division of Clinical Pharmacology
at that time.
Unfortunately, 1968 and 1969 were difficult years
in the development of the medical practice plan
for members of the full-time Faculty of the
Clinical Departments at Jefferson. Dr. Capelli
decided to resign his full-time position as Director
of the Division of Clinical Pharmacology and
enter private medical practice. Dr. Wesson was
then appointed Director. Other members of the
Division at that time were Drs. Peter Amadio of
Wallace Laboratories, Elmer Funk, Jr., and
Thomas N. Gates of Merck Sharp & Dohme, and
Charles K. Gorby of Lankenau Hospital. This
original Division of Clinical Pharmacology
continued through June 30, 1973, when it was
discontinued because of lack of financial support.

The Present Clinical
Pharmacology Division
The present Clinical Pharmacology Program began
in 1975 when senior officers of the Merck Sharp &
Dohme Research Laboratories (MSDRL)
approached their counterparts as Thomas Jefferson
University with a proposal for a collaborative
clinical pharmacology venture. The proposed
arrangement had a number of unique
characteristics. Unlike units funded by other
pharmaceutical companies elsewhere, the
administration and staffmg of the Jefferson Unit
would be entirely under the control of the
University even though the major portion of the
financial support would come from MSDRL. An
advisory committee with representatives from both

institutions initially oversaw the function and
direction of the Unit. Although the major Unit
effort would be committed to MSDRL studies,
other projects from a variety of funding sources
could be undertaken. The Unit would be a
Division of the Department of Medicine and be
located on the fifth floor of the 1907 Main
Hospital Building. A letter of understanding that
included these provisions was signed by officers
from both institutions in December of 1976.
Jefferson officials prominent in these early
negotiations were Dr. Francis J. Sweeney, Jr., VicePresident, Medical Affairs; Dr. William Kellow,
Dean of Jefferson Medical College; Mr. Byron
Irwin, Associate Administrator, Thomas Jefferson
University Hospital; Dr. Frank D. Gray,
Chairman and Professor of Medicine; and Dr.
C. Paul Bianchi, Chairman and Professor of
Pharmacology. MSDRL was represented by Dr.
William B. Abrams (Jefferson, 194-7), Executive
Director of Clinical Research; Dr. Richard O.
Davies, Director, Clinical Pharmacology; Dr.
Hubert C. Peltier, Vice-President for Medical
Affairs; and Mr. Donald S. Brooks of MSDRL
Legal. A letter of understanding was signed by
Mr. George M. Norwood, Jr., interim President
of Thomas Jefferson University, for Jefferson, and
by Dr. P. Roy Vagelos, President of MSDRL, for
Merck.

• Research
A search committee was formed by the University,
and in May 1977 Dr. Roger Ferguson was
recruited to be the first Director. He received his
medical degree at the University of Utah, then
served his residency and was an M.S. in
Pharmacology at the University of Iowa. Dr.
Ferguson was active in antihypertensive drug
research at Michigan State University. He had
recently spent a sabbatical leave with Dr. Hans
Brunner in Lausanne, Switzerland, where Dr.
Ferguson undertook the first human investigation
of a new class of agents, the angiotensin
converting enzyme inhibitors (ACE inhibitors).
Dr. Ferguson recruited the initial staff, and the
first clinical study was undertaken in the fall of
1977. Peter H. Vlasses, Pharm.D., was appointed
in 1978 as Assistant Director. Dr. Vlasses received
his Doctor of Pharmacy degree from the
Philadelphia College of Pharmacy and Science
(PCPS); his special interest was in cardiovascular
drug research.
Administratively, liaison with the Unit was the
responsibility of Dr. William B. Abrams, Executive
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Director of Clinical Research at Merck.
Collaboration was initially implemented by Drs.
David Cooper and Jolm Schrogie through Dr.
Davies. In 1980, Dr. Abrams asswned rhe liaison
function directly. Dr. Abrams graduated from
Jefferson in 1947, interned in Atlantic City, and
received postgraduate training at the Children's
Hospital of Philadelphia, Philadelphia General
Hospital, and Sr. Louis University. I Ie is a past
President of the American Society for Clinical
Pharmacology and Therapeutics. Dr. Abrams
joined Merck in 1975, having previously been
employed by Ayerst Laboratories and
Hoffmann-La Rochc, Inc. In order to facilitate the
arrangements between the institutions, Thomas
Jefferson University offercd adjunct faculty
positions to the Merck liaison officers. Thus, Dr.
Abrams has been Adjunct Professor of Medicine
since 1977. He received strong support relative to
this liaison from Marvin E. Jaffe, M.D.,
Vice-President of Clinical Research, who was also
a Jefferson Medical College graduate and a
member of the adjunct faculty in neurology.
The initial direction involved active pursuit of
ACE inhibitors and expansion of the Division's
human research capabilities. Over the next several
years, key personnel additions included Brian N.
Swanson, Ph.D., Heschi H. Rotmensch, M.D.,
and, in a collaborative arrangement with PCPS,
Mario L. Rocci, Jr., Ph.D. Dr. Swanson had
expertise in assay development, especially
high-performance liquid chromatography. Dr.
Rotmensch brought expertise in
pharmacodynamics, whereas Dr. Rocci was skilled
in pharmacokinetic laboratory and data analysis. In
this same period, the Unit underwent physical
expansion, funded by MSDRL, to accomodate
new laboratory and computer data processing
facilities. With rhe assembling of this critical mass,
the Division became very productive in its clinical
research efforts.
The evaluation of ACE inhibitors in
hypertension at Jefferson included dose-response,
mechanism of action, comparative efficacy, and
drug interaction studies with captopril, enalapril,
and lisinopril. The ACE inhibitors subsequently
have received extensive use in hypertension and
congestive heart failure. The important Jefferson
contributions to this field are summarized in a text
edited by Drs. Ferguson and Vlasses, published
in 1987.
Over its ten-year existence, Ij1 studies of new
compounds were conducted by the Division of
Clinical Pharmacology. Important contributors
over this time also included Louis J. Reilly, Jr.,

M.D., and Michael D. Cressman, D.O. A wide
range of therapeutic categories was represented,
including diuretics, nonsteroidal anti-inflammatory
drugs, antibiotics, ophthalmologic agents, and
psychotl1erapeutic drugs. In general, this was an
unprecedented period of research productivity in
this field.
Many studies at Jefferson characterized the
pharmacokinctics of the different investigational
compounds in man. The special emphasis on
pharmacodynamic assessments in these trials led to
the development or application of many clinical
and laboratory drug evaluation techniques.
Important contributions in healthy volunteer
experiments includcd the unraveling of the
differential clinical pharmacology of the
enantiomers of indacrinone, a uricosuric diuretic,
and the assessment of systemic beta-blockade after
dermal and ophthalmic application of timolol and
other compoundS. Parviz Mojaverian, Ph.D.,
undertook studies with the Heidelberg capsule, a
pH-sensitive, radiotelemetric device. These studies
led to important contributions to the
understanding of the physiology of the
interdigestive migrating myoelectric complex and
pharmaceutical considerations dealing with gastric
indigestible dosage forms (for example, enteric
coated and sustained-release tablets). The nature
and mechanism of many drug-drug interactions
have also been evaluated. Close collaboration
between Jefferson and Merck clinical and basic
scientists evolved over this time. Extremely
efficient processing of studies has resulted,
facilitated by industrywide innovations in research
data telecommwlications. To date, well over 125
research and scholarly publications bearing the
Jefferson affiliation have resulted from tl1ese
evaluations. Recent research efforts have
emphasized drugs affecting the prostaglandins and
leukotrienes and their involvement in
inflammation, pain, and local vascular regulation.

• Education, and Service
In addition to research efforts, the Division of
Clinical Pharmacology has participated actively in
Jefferson Medical College's education and service
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programs. Since 1977 the Division has offered a
well-received fourth-year medical student elective
course in clinical pharmacology employing a
case-simulation format. Twelve postdoctoral
(M.D., Ph.D., or Pharm.D.) Fellows as well as
graduate and undergraduate medical and pharmacy
students received training in the Division. Many
faculty held cross-appointments in pharmacology,
and a close working relationship evolved with
many physician collaborators and the Hospital's
Department of Pharmacy, directed by Joe E.
Smith, Pharm.D. Unit faculty have served as
teacher for the medical students, provided
consultation for hospitalized and ambulatory
patients on drug-related problems, served on
pertinent comittees (for example, Pharmacy and
Therapeutics, the Institutional Review Board) and
have contributed to a variety of community
services and professional organizations, both
locally and nationally. In this regard, Dr. Vlasses
was a founding member of the American College
of Clinical Pharmacy in 1979, subsequently served
as national President in 1983, and was honored as
a Fellow in [985.
Dr. Ferguson left Jefferson in 1985 to aSSlUue the
Chair in Medicine at the University of Nevada at
Reno. Discussions between Jefferson and MSDRL
officers at that time led to a reaffirmation of the
commitment of each parry. The desire of both
institutions was to maintain the activities in
clinical research and to add investigations of a
basic and mechanistic nature to this collaborative
research effort. A revised letter of understanding,
with funding commitment for a five-year renewal
period, was executed in 1986. Key figures in tlle
discussions leading to the continuation agreement
in addition to Dr. Abrams were Willis C.
Maddrey, M.D., Chairman of the Department of
Medicine; Lewis W. Bluemle, M.D., President of
Thomas Jefferson University; Marvin Jaffe, M.D.,
Vice-President of Clinical Research; and Edward
Scolnick, M.D., President of MSDRL.
At this time, the role of the MSDRL Liaison
was assmned by Dr. Keith H. Jones, Executive
Director for Clinical Pharmacology. Dr. Jones
received his medical degree at the University of

Wales in 1966 and a Diploma in Pharmaceutical
Medicine from the Royal College of Physicians in
London in 1976. Prior to coming to MSDRL in
1979, he was employed by Beecham
Pharmaceuticals, Surrey, England for ten years.
Dr. Jones was appointed Adjunct Professor of
Medicine at Jefferson in 1986.
A national search by Dr. Maddrey led to the
recruitment of Thorir D. Bjornsson, M.D. as
Director of the Division of Clinical Pharmacology
in 1986. Dr. Bjornsson received his medical degree
at the University of Iceland. He trained in clinical
pharmacology at Stanford University and held
previous faculty positions in clinical pharmacology
at Duke University. He serves on the
pharmacology study section of the National
Institutes of Health.
As an expression of the commitment to clinical
pharmacology and the desire to expand the scope
of Divisional research, Dr. Maddrey provided
funds for construction of a new Divisional facility
encompassing II,OOO square feet of laboratory,
clinical, and office space in the new Medical Office
Building. The new Divisional facilities opened in
April, 1987.
Dr. Bjornsson established three Sections within
the Division: the Laboratory for Thrombosis and
Atherosclerosis Research, which he heads; the
Clinical Research Unit, headed by Dr. Vlasses;
and the Laboratory for Investigative Medicine,
headed by Dr. Rocci. Each Section has specific
interests and functions as well as collaborative
activities. Merck-funded projects as well as
research programs funded tllrough other sources
(federal, foundation, and other pharmaceutical
companies) are now commonly undertaken by the
Divisional faculty. Divisional faculty are
committed to developing a stronger program in
drug development through clinical and basic
research and training of future clinical
pharmacologists. Dr. Bjornsson received a
prestigious Pharmaceutical Manufacturers'
Association Development Grant for Clinical
Pharmacology in 1987 for expansion of the
Division mission.
Thus, the decade spanning 1977-1987 has seen
the evolution of a nationally recognized progranl
in clinical pharmacology at Jefferson that would
not have been possible without the strong
collaborative venture with MSDRL. As the second
decade begins, enthusiasm runs high for continued
growth and recognition in an even broader realm
of research as advances in biotechnology provide
novel agents for the treatment of human disease.
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